Top Seattle, WA Biotech Companies (46)
Trusted by the world's leading organizations, Point B is a consulting firm that works at the intersection of expertise, industry insight, and transformative technology. This collaborative approach enables you to solve your most important challenges, by bringing together the right mix of talent and technology to deliver greater value and impact. With over 850 associates in the US and 3000+ consultants around the world through our Nextcontinent partnership, we work where you do to deliver the change you seek.
Outpace Bio is a venture-backed biotechnology company building a platform to create next-generation smart cell therapies. Our world-class scientific team is developing cell therapies that intervene in complex biology in ways that small molecules and biologics cannot. Our rich platform combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. We create mechanism-driven solutions tailor-made to dramatically improve efficacy and safety. Our partnership business model will accelerate the clinical validation of our platform and the development of truly curative therapies. We value teamwork, creativity, integrity, rigor, and passion for science. At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for pro-innovation/pro-patient policies.
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Parse Biosciences is a Seattle-based startup providing researchers access to the most scalable single cell sequencing platform available. With technology founded on the principles of SPLiT-seq, published in Science in 2018, Parse Biosciences' mission is to accelerate progress in scientific research as well as human health. Single-cell sequencing has already enabled groundbreaking discoveries that have led to new understandings in cancer treatment, tissue repair, stem cell therapy, the immune system and much more. At Parse Biosciences we provide researchers with the ability to perform single cell sequencing with unprecedented scale and ease.
At A-Alpha Bio, we aim to accelerate target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions. Current approaches for measuring protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. AlphaSeq is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. We are seeking industry partnerships to evaluate the use of AlphaSeq for a variety of drug development applications. A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.
We sequence whole plasmids, amplicons, whole bacterial genomes, and colonies overnight, without the need for primers and minipreps. Plasmidsaurus is on a mission to accelerate new cures and promote a healthier planet by unlocking new levels of productivity in scientists using DNA tools to bring their ideas to life. The company’s DNA sequencing services are used daily by thousands of innovators, including Nobel prize winners, dynamic biotech startups, pharmaceutical companies, research labs, and DIY biohackers. Plasmidsaurus’s global network of labs operates day and night to enable world-changing discoveries. Sequence Everything!
Just – Evotec Biologics is an integrated design company focused on technologies that will accelerate development of biotherapeutics and substantially reduce their manufacturing cost.
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases -- such as cancer, autoimmune conditions, and infectious diseases -- are diagnosed and treated. For more information, please visit adaptivebiotech.com.
Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.
Bridge the data gap. Augment your experimental data with AI-generated datasets and harmonized public data to get insights in minutes instead of months.
Lightspeed Microscopy Inc. reimagines pathology by providing a full-stack solution to nondestructively image large tissues in 3D at sub-cellular resolution. Its novel chemistry, patented high-throughput light-sheet microscope, and cloud-based AI analysis software adds a new dimension to pathology. Lightspeed, spun-out of the University of Washington and co-founded by Nick Reder in 2018, is based in Seattle, WA.
Adaptive Symbiotic Technologies is a dynamic agricultural biotech company based in Seattle, Washington, U.S.A. We focus on the research and production of symbiotic plant microbes as agricultural crop treatments for farmers. This symbiotic relationship between crops and microbes allows plants to tolerate abiotic stress and increase uptake of soil nutrients naturally. This dynamic relationship is a cooperative approach to making plants healthier and more adaptable to increasing climate changes around the globe. We are continually searching for new microbial symbionts and organic plant treatments to increase agricultural sustainability and farmers' profitability. Our intent is to make this technology available to small and large-scale farmers in first world and developing nations to help increase crop yields and decrease human hardship.
Kineta is a privately held emerging biotech company that was founded in 2008. Our mission is to develop novel immunotherapies that transform patients’ lives.
Halo-Bio RNAi Therapeutics Inc. is an early stage company.
Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis.
Myosana Therapeutics, Inc. is pioneering efforts in developing non-viral targeted gene therapy for skeletal muscle and cardiac diseases. Our current focus is Duchenne muscular dystrophy (DMD) but our platform is applicable to any genetic muscle disease. Current gene therapy for skeletal and cardiac muscle diseases uses Adeno Associated Virus (AAV) to deliver small healthy genes or portions of large genes, to the cells that contain unhealthy (mutated) genes. AAV has numerous limitations, including limited gene size capacity (5 kilobases), precluding its use for many larger genes like dystrophin. Furthermore, many individuals may have naturally occurring antibodies against AAV or will develop antibodies after their first treatment, limiting treatment to a single dose. The Myosana Platform Technology bypasses the limitations of AAV delivery and, therefore, is much more versatile. • The Myosana platform does not use viruses to deliver genes to the cells. • The new technology can deliver genes of any size. • The Myosana Non-Viral delivery method is much less likely to elicit an immune response, enabling repeated dosing over months or years. • The Myosana platform targets the healthy gene to skeletal and cardiac muscle cells. The novel gene therapy approach we have developed will provide new treatments for many diseases of skeletal and cardiac muscle. Our current focus is DMD, but we expect to use the platform to treat other muscular dystrophies and congenital myopathies.
Resolve Therapeutics is a biotechnology company developing an exciting new biologic compound for the treatment of lupus that inhibits a key upstream step in the interferon cascade. The company is based on technology and compounds exclusively licensed from the University of Washington. The company will develop these compounds through early clinical testing and partner with a pharmaceutical company for late stage clinical development and commercialization.
Work Your Passion. Live Your Purpose.
Industry
Work Your Passion. Live Your Purpose.
